Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
1,285
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
stocks
Here’s 3 Top Rated ASX shares for 2026
stocks
Undervalued Aussie e-commerce winner
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 22.30 | 0.25% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,027.90 | 431.05 | -1.63% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,720.80 | 18.20 | 0.21% |
| SSE Composite Index | 4,081.56 | 4.22 | -0.10% |